Business context and reporting period
The supplied filing is Aeglea BioTherapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 8, 2022. The request metadata identifies Spyre Therapeutics, Inc.; the filing text itself does not identify Spyre, so the company identity should be verified.
Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapies for rare metabolic diseases. Its lead candidate was pegzilarginase for Arginase 1 Deficiency; AGLE-177 was in Phase 1/2 development for Homocystinuria, and AGLE-325 was in preclinical development for Cystinuria. The company had 101 employees at year-end and operated as one reporting segment.
Financial performance and position
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Total revenue | $18.7 million | $0 | New revenue |
| Research and development expense | $57.1 million | $59.6 million | Down 4% |
| General and administrative expense | $27.3 million | $21.8 million | Up 25% |
| Total operating expenses | $84.4 million | $81.5 million | Up 4% |
| Loss from operations | $(65.6) million | $(81.5) million | Improved 19% |
| Net loss | $(65.8) million | $(80.9) million | Improved 19% |
| Net loss per share | $(1.00) | $(1.52) | Improved |
| Operating cash flow | $(53.7) million | $(75.8) million | Improved |
| Year-end cash, cash equivalents, marketable securities and restricted cash | $95.0 million | $91.9 million | Up $3.1 million |
2021 revenue consisted of $12.0 million from the Immedica license and $6.7 million of development fee revenue. The company generated no commercial product revenue. Revenue recognition included significant estimates regarding performance obligations, standalone selling prices and progress toward development activities.
Year-end total assets were $109.9 million, including $78.0 million of marketable securities and $15.1 million of cash and cash equivalents. Total liabilities were $26.0 million and stockholders’ equity was $83.9 million. The filing states that the company had no debt or credit facility, although it had lease liabilities and other contractual obligations.
Net cash used in investing activities was $22.6 million, primarily reflecting purchases of marketable securities exceeding maturities. Financing activities provided $1.4 million, principally from stock option exercises and employee stock purchases, partially offset by finance lease payments. The company reported no dividends.
Material changes versus the prior comparable period
- The company entered into an exclusive license and supply agreement with Immedica for pegzilarginase commercialization in Europe, the United Kingdom, Switzerland and specified Middle Eastern territories. Immedica paid a $21.5 million upfront amount; the company recognized $18.7 million of related revenue in 2021 and recorded $3.6 million of deferred revenue at year-end.
- Potential additional consideration under the Immedica agreement included approximately $125.0 million of regulatory and commercial milestones and royalties in the mid-20% range on net sales in the licensed territories. These amounts were not recognized as revenue at year-end.
- Research and development expense decreased because certain pegzilarginase manufacturing activities and AGLE-177 formulation and stability work were completed, partly offset by higher clinical, nonclinical, BLA-related and personnel costs.
- General and administrative expense increased by $5.5 million, primarily due to increased personnel costs, commercial planning and commercial infrastructure.
- Operating cash burn declined from $75.8 million to $53.7 million, but total cash, cash equivalents and restricted cash declined from $91.9 million to $17.0 million because funds were shifted into marketable securities; total liquidity including marketable securities was $95.0 million.
- Shares outstanding increased to 49.4 million at December 31, 2021 from 48.0 million at December 31, 2020. In addition, 16.6 million pre-funded warrants remained outstanding and could result in substantial dilution for nominal or no additional consideration.
Clinical progress, outlook and risks
In December 2021, the PEACE Phase 3 trial of pegzilarginase met its primary endpoint, showing an 80% reduction in mean plasma arginine after 24 weeks compared with baseline, with p<0.0001. Normal plasma arginine levels were achieved in 90.5% of treated patients versus none in the placebo arm. Mobility results showed positive trends but did not achieve nominal statistical significance: GMFM-E had p=0.1087 and the 2-Minute Walk Test had p=0.5961.
Management planned to submit a U.S. Biologics License Application in the second quarter of 2022 and expected Immedica to submit a European application during 2022. However, the filing disclosed preliminary FDA feedback that the PEACE results, as described at a high level, did not appear to provide substantial evidence of effectiveness to support a BLA. The FDA raised concerns regarding the primary endpoint, trial duration and adequacy of clinical outcome evidence. Additional studies or follow-up could therefore be required, and approval was uncertain.
AGLE-177 completed dosing in its first Phase 1/2 cohort in 2021. The company reported no safety concerns and reductions in total homocysteine in all patients in that cohort. It advanced to a subcutaneous 0.45 mg/kg cohort and expected initial clinical data in the second half of 2022. AGLE-325 was planned to enter IND-enabling studies in 2022.
Management estimated that the $95.0 million of liquidity at December 31, 2021 would fund operations into the first quarter of 2023. The auditor’s report and management’s disclosures nevertheless stated that substantial doubt existed about the company’s ability to continue as a going concern because of recurring losses, expected future losses and the need for additional capital. Management expected to seek equity, debt, collaboration, licensing or other strategic financing.
- COVID-19 had caused missed dosing, enrollment delays, site disruptions, supply-chain risks and potential regulatory delays.
- The company relied on contract research and manufacturing organizations and had no internal commercial-scale manufacturing facilities or redundant bulk drug substance source.
- Clinical, regulatory and manufacturing success remained uncertain, particularly because pegzilarginase’s pivotal trial did not demonstrate nominal statistical significance on prespecified clinical mobility endpoints.
- Market acceptance could be limited by competing therapies, reimbursement and pricing pressure, small addressable patient populations and difficulty identifying patients with rare diseases.
- Intellectual property protection depended partly on licensed rights, including University of Texas agreements that included milestone payments, royalties and potential termination rights.
Most important facts for an investor to verify
- Confirm that this Aeglea filing is the intended document for the Spyre Therapeutics request.
- Verify the FDA’s subsequent action on the planned pegzilarginase BLA, including whether it was filed, accepted, approved, delayed or rejected.
- Reconcile liquidity by distinguishing cash and cash equivalents of $15.1 million from total liquidity of $95.0 million including marketable securities and restricted cash.
- Assess the timing and terms of any subsequent financing required to address the going-concern uncertainty and expected cash runway through the first quarter of 2023.
- Track clinical data for AGLE-177 and the status of AGLE-325 IND-enabling studies.
- Evaluate dilution from the 16.6 million outstanding pre-funded warrants, stock options and future equity financings.
- Review the Immedica agreement’s deferred revenue, milestone probability, royalty terms and remaining obligations.
- Confirm whether COVID-19, manufacturing capacity, regulatory feedback or clinical endpoint concerns changed the development timetable after the filing date.